Abstract:BACKGROUND: It is estimated that about 30% of esophageal cancer (EC) patients are over 70 years old. Therefore, there is less evidence on the diagnosis and management of elderly EC patients. It is important to explore how elderly EC patients benefit from radical radiochemotherapy regimens, including the target area of radiotherapy (RT), radiation dose and fraction, and choice of chemotherapy drugs.AIM: To compare the efficacy of involved-field intensity-modulated RT (IF-IMRT) combined with S-1 vs RT alone in the treatment of elderly EC patients in terms of safety, short-term response, and survival.METHODS: Thirty-four EC patients aged > 70 years were prospectively enrolled between December 2017 and December 2019. Based on the random number table, they were divided into an IF-IMRT + S-1 group and an IF-IMRT alone group, with 17 patients in each group. All patients were treated with IF-IMRT at a dose of 50.4-56 Gy in 28-30 fractions (1.8-2 Gy/fraction, 5 fractions/wk). Oral S-1 was administered concomitantly in the IF-IMRT + S-1 group for 14 consecutive days, and a second cycle was started 7 d after drug withdrawal. After RT, 4 cycles of S-1 treatment were offered as the consolidation chemotherapy. The safety, short-term response, and survival were observed after the treatment.RESULTS: As of April 2022, these 34 patients had been followed up for 15.2-32.5 mo, with a median follow-up period of 24.5 mo. Complete efficacy indicators were obtained from all the patients. The objective response rate was 88.2% vs 76.5%, respectively, in the IF-IMRT + S-1 group and the RT alone group, where as the disease control rate was 100% vs 82.4%, respectively. The incidence of adverse events including grade 1-2 fatigue, granulocytopenia, thrombocytopenia, anemia, radiation esophagitis, radiation-induced skin injury, and radiation-induced lung injury was not significantly different between these two groups, so was the incidence of the grade 3 radiation esophagitis (0% vs 5.7%). The rate of progressive disease (PD) was 52.9% (n = 9) in the IF-IMRT + S-1 group and 64.7% (n = 11) in the RT alone group. The median progression-free survival (PFS) was 23.4 mo vs 16.3 mo, and the 2-year PFS rate was 42% vs 41.2%. The median overall survival (OS) was 27.0 mo vs 23.0 mo, and the 2-year OS rate was 58.8% vs 47.1%. Multivariate analysis showed that age was a significant prognostic factor (P = 0.0019); patients aged < 75 years had a significant survival advantage over patients aged ≥ 75 years. The locations of EC also affected the prognosis. In the IF-IMRT + S-1 group, the number of chemotherapy cycles was a significant prognostic factor (P = 0.0125), and the risk of PD was significantly lower in EC patients who had received 6 cycles of chemotherapy than those who had received 2-5 cycles of chemotherapy.CONCLUSION: Compared with IF-IMRT alone, IF-IMRT + S-1 shows the benefits of preventing PD and prolonging survival without increasing adverse reactions. Therefore, this concurrent radiochemotherapy deserves clinical application.

Radiotherapy for Elderly Esophageal Cancer

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Intensity Modulated Radiation Therapy for Elderly Patients with Esophageal Cancer: Our Experience

Radiotherapy for patients with esophageal cancer aged 80 years or older: A 16-year experience

Treatment strategies for elderly patients with locally advanced esophageal cancer: a systematic review and meta-analysis

Prognosis of radiotherapy for esophageal cancer in elderly patients exceeding seventy-five years old

[Application of Radiotherapy in Perioperative Comprehensive Treatment for the Elderly with Rectal Cancer].

Late Course Accelerated Hyperfractionation Radiotherapy Combined with Chemotherapy for Elderly Patients with Esophageal Carcinoma

Comparison of involved-field intensity-modulated radiotherapy combined with S-1 vs radiotherapy alone for elderly patients with esophageal cancer

Conformal Radiotherapy for Esophageal Carcinoma in High-aged Patients

Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes; A Systematic Review and Pooled Analysis

Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma

Impact of Chemotherapy and Radiotherapy on the Survival of Elderly Esophageal Cancer Patients Undergoing Surgery: a SEER Database Analysis

The effect of surgery plus chemoradiotherapy on survival of elderly patients with stage II–III esophageal cancer: a SEER‐based demographic analysis

A Phase Ⅱ Prospective Study on Raltitrexed Combined with Concurrent Radiotherapy for Elderly Esophageal Carcinoma

Clinical Features, Outcomes and Treatment-Related Pneumonitis in Elderly Patients with Esophageal Carcinoma.

Efficacy of concurrent chemoradiotherapy with S-1 vs. radiotherapy alone for elderly patients with esophageal cancer: a meta-analysis

Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial

Comparative Study of Radiotherapy Plus Erlotinib Versus Chemoradiotherapy for Elderly Patients with Esophageal Cancer: a Propensity Score-Matched Analysis.

Treatment Patterns and Outcomes of Elderly Patients With Potentially Curable Esophageal Cancer